Stablepharma and AJ Vaccines sign strategic Letter of Intent

Stablepharma and AJ Vaccines have drafted a primary commercial distribution deal for SPVX02.

The vaccine is a fridge-free adult booster vaccine designed to prevent tetanus and diphtheria infections globally. 

When the distribution agreement has been settled, AJ Vaccines will be the exclusive European marketing authorisation holder of SPVX02, while Stablepharma will exclusively supply the product to AJ for distribution. 

The agreement will be a step forward for Stablepharma, as the company endavours to distribute SPVX02 globally in the coming years. 

VP of Business Development & Commercial Operations at AJ Vaccines, Søren Skjold Mogensen, commented: 

We are pleased to have reached an agreement with Stablepharma. Their innovative approach to biotech aligns closely with their mission to make vaccines and other temperature-sensitive pharmaceutical products more accessible to everyone, reducing reliance on the global cold chain.

The full terms of the proposed agreement are likely to be finalised in due course.

“With this announcement, we have solidified our belief in the commercial future of fridge-free vaccines, established the foundations of a strong distribution partnership with an established European vaccine manufacturer, and we are closer than ever before to realising our vision of making fridge-free vaccines and pharmaceuticals a reality,” added Özgür Tuncer, CEO & Executive Director, Stablepharma Ltd. 

“By partnering with pharmaceutical manufacturers, we aim to improve global access to vaccine and pharmaceutical products, whilst reducing dependence on the global cold chain”.